Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.


Pharmaceutical Price Controls in OECD Countries
Kevin A. Hassett, Department of Commerce, 8-3-04

The U.S. is the last member of the OECD to allow market prices to prevail for pharmaceutical products. Introducing price controls into this market would have adverse affects not only for the U.S., but possibly for global health as well.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000